Department of Biostatistics and Informatics, University of Wisconsin School of Medicine and Public Health, Wisconsin, USA
Review Article
Ivermectin in Covid-19: Important and Timely Updates for Family Medicine Physicians
Author(s): Andreea Molnar*, Stephanie Lau, Maja Berges, Raymond B Masa, Joshua J. Solano, Scott M Alter, Lisa M Clayton, Richard D Shih, David L DeMets, Dennis G Maki and Charles H Hennekens
Ivermectin is not approved by the United States (US) Food and Drug Administration (FDA) for the treatment or
prevention of COVID-19. Nonetheless, ivermectin prescriptions increased 11-fold from 3589 per week pre-COVID-19
to 39,102 by early 2021. In recent polls, 85% of the public trust their family medicine physicians as a source of
reliable information on COVID-19 vaccinations. Ivermectin is FDA approved to treat intestinal strongyloidiasis and
onchocerciasis orally, as well as ectoparasites and skin conditions topically. Possible side effects include skin rash,
nausea, vomiting, diarrhea, stomach pain, facial or limb swelling, dizziness, seizures, confusion, hypotension, and liver
injury. The United States (US) National Institutes of Health, World Health Organization, US FDA and European
Medicines Agency have all advised against ivermectin for treatment or pre.. View More»
DOI:
10.35248/2327-5146.21.9.357
